; fasting glucose X100 mg dl À 1 ; waist circumference: X102 cm men, women X88 cm) or MHO (o2 risk factors). Whole-body bone mineral density and content, percent body fat, fat mass, lean mass and trunk adipose tissue mass were measured with dual-energy X-ray absorptiometry. Visceral (VAT), subcutaneous (SAT) and total abdominal adipose tissue (TAT) were measured with computed tomography. Gender-specific general linear regression models were used to determine differences in body composition between MHO and OA controlling for age, race, smoking status and menopause status. In men, MHO had lower fat mass (kg and %), trunk adipose tissue, VAT, SAT, TAT and lean mass compared with OA. MHO women had lower fat mass (kg), lean mass, trunk adipose tissue, VAT and TAT when compared with OA women. In conclusion, OA and MHO cardiometabolic profiles are characterized by differences in body composition consistent between genders.
INTRODUCTION
Obesity has been recognized as a complex and heterogeneous condition, whereby despite the presence of excess adipose tissue, varying cardiometabolic risk may occur. Consequently, different obesity phenotypes exist and have been identified as metabolically healthy obese (MHO) and metabolically abnormal obese (OA). Those characterized as MHO have favorable levels of cardiometabolic risk factors, [1] [2] [3] lower risk for cardiovascular disease, 4 diabetes 4 and mortality 5 when compared with their OA counterparts.
Comparisons of body composition between MHO and OA have been limited to mostly women 1, [6] [7] [8] [9] [10] and/or non-US-based adults. 6, 9, 11, 12 The few US-based studies have had combined statistical analyses for men and women, 13 who have known differences in adipose tissue storage. 14, 15 Previous studies have also mostly focused on white populations, [11] [12] [13] despite body composition differences between adults of different ethnicities. 14 Further, we know that body composition changes with aging, 14, 16 and many of the aforementioned studies have focused on older post menopausal women. 1, 2, 7, 8, 10 Therefore, the purpose of this study is to determine whether measures of body composition differ between MHO and OA among US men and women.
SUBJECTS AND METHODS
The sample included 395 obese (body mass index X30 kg m À 2 ) men and women (X18 years of age) from the Pennington Center Longitudinal Study (PCLS). PCLS is made up of volunteers visiting the Pennington Biomedical Research Center in Baton Rouge, Louisiana, USA. 17 The current cross-sectional study is limited to participants who were screened between 1996 and 2010 and had baseline dual-energy X-ray absorptiometry (DXA) whole-body scans, abdominal computed tomography (CT) scans, blood draws and were not pregnant. Each volunteer provided their written informed consent. All PCLS procedures and secondary analyses were approved by the Pennington Biomedical Research Center Institutional Review Board.
Whole-body bone mineral density (BMD; g cm À 2 ), bone mineral content (BMC; kg), percent body fat (%), fat mass (kg), lean mass (kg) and trunk and appendage adipose tissue mass (kg) were measured with Hologic (Bedford, MA, USA) whole-body DXA scanners as previously described. 17 ) and total adipose tissue (TAT; cm 2 ) were measured with CT, as previously described. 17 A single cross-sectional image at the L4-L5 intervertebral space was obtained, and CT images were analyzed at Pennington Biomedical Research Center with commercially available software (Analyze; Analyze Direct, Rochester, MN, USA).
Resting systolic and diastolic blood pressures were obtained after a 5-min rest, with the participant in a semi-recumbent position in a quiet room using the manual method or an Omron automatic measuring device (Omron, Bannockburn, IL, USA). Each measurement was taken twice, 1-2 min apart, and the average of the two measurements was used in analyses.
Blood was collected following a minimum of a 10-h fast, and within 60 days of the body scans. Glucose and lipids were analyzed on a Beckman Coulter DXC600 (Beckman Coulter, Brea, CA, USA). Adults were classified as OA (X2 cardiometabolic risk factors: blood pressure X130/85 mmHg; triglycerides X150 mg dl À 1 , high-density lipoprotein cholesterol men o40, women o50 mg dl À 1 ; fasting glucose X100 mg dl À 1 ; or waist circumference X88 cm women, X102 cm for men) or MHO (0 or 1 cardiometabolic risk factor).
Participants were classified as 'non-smokers', 'current smokers' or 'former smokers'. Menopausal status was determined from women X55 years of age, or from those who indicated that they can no longer have children because of achieving menopause were considered to be post menopausal.
Statistical analysis
All analyses were performed with SAS 9.3, and statistical significance was defined as Po0.05. Non-normally distributed variables were log-transformed for analysis (lean mass, VAT, BMD and BMC); however, the means were reverse-transformed for presentation of results. Gender-specific general linear models were used to determine differences in body composition between MHO and OA controlling for age, race, smoking status and menopausal status (in women).
RESULTS
The PCLS sample was composed of 66% women; 38% African American and ranged in age from 18 to 68 years of age (mean ± s.d.: 40.6 ± 13.2 years). MHO adults were significantly younger in both men and women, with a lower weight, body mass index and waist circumference compared with OA (Table 1) . In both men and women with the MHO profile, systolic blood pressure, diastolic blood pressure, glucose and triglycerides were all significantly lower, whereas high-density lipoprotein cholesterol was significantly higher when compared with OA. Figure 1 presents some of the body composition variables from the DXA and CT scans. Once adjusted for covariates, results from the DXA scan showed that men with MHO had lower percent fat (MHO versus OA mean±s.e.; P-value for difference: 27.1±0.9 versus 29.1 ± 0.7; P ¼ 0.03), lower fat mass (26.8 ± 1.4 versus 31.1 ± 1.1 kg; P ¼ 0.002), lower trunk adipose tissue (13.1 ± 0.9 versus 16.4±0.7 kg; P ¼ 0.0001) and lower lean mass (73.5±1.2 versus 75.5±1.4; P ¼ 0.04) compared with OA men. No significant differences were found in men between MHO and OA profiles for BMD, BMC or appendage adipose tissue. From the adjusted CT analyses, there were significant differences between MHO and OA in men for VAT 112.9 ± 12.9 versus 139.0 ± 9. In the adjusted DXA models, women with MHO phenotypes had lower fat mass (35.4 ± 1.0 versus 37.6 ± 0.8; P ¼ 0.007 kg, lower trunk adipose tissue (16.1 ± 0.6 versus 17.9 ± 0.5 kg; P ¼ 0.0001), lower lean mass (49.9±0.9 versus 52.5±0.8 kg; P ¼ 0.0004), when compared with OA women. There were no significant differences in women between MHO and OA for % fat, appendage fat, BMD or BMC. In the CT-adjusted models, women with MHO had lower VAT (88.9±8.5 versus 112.2±6.9 cm 2 ; Po0.0001) and TAT (605.2±21.0 versus 648.6±17.1 cm 2 ; P ¼ 0.008) but no significant differences for SAT when compared with their OA counterparts.
DISCUSSION
In the current analyses, OA and MHO cardiometabolic profiles are characterized by differences in body composition. Men and women have differences between MHO and OA for overall and centralized adipose tissue, as well as lean mass.
Lower levels of VAT have been confirmed in many other studies in women. 1, 2, 6, [8] [9] [10] We also found that women with the MHO phenotype have lower VAT in comparison to their OA counterparts utilizing our cardiometabolic clustering definition. Currently, we do not know of other studies that exclusively studied VAT in MHO and OA men. However, Stefan 11 did not find significant differences in VAT between MHO and OA in a combined sample of German men and women, although these analyses were not gender-specific. Thus, the current study suggests regional and central adipose tissue differences for both men and women between MHO and OA phenotypes.
Previous studies have confirmed our findings that for women, those with the MHO phenotype, have lower lean mass 1, 8, 10, [18] [19] [20] and no significant differences for SAT 1, 9, 10, 19 when compared with the OA phenotype. Other studies that have included both men and women have shown equivocal results; some show significantly less fat mass in MHO, 13 whereas others have not shown significant differences between MHO and OA phenotypes for fat mass, 11, 12 fat-free mass, 12 or VAT, SAT and TAT. 11 However, these studies did not analyze body composition separately in men and women for these body composition variables. 11, 12 We believe that this may be the first study to examine SAT, lean mass and fat mass exclusively in men between MHO and OA phenotypes. For men, we did find significantly less fat mass, lean mass, VAT and TAT in men with MHO phenotype; however, these results should be replicated in future studies. A strength of the current study is that it employs a sample of US men and women with a wide range of age (18-64 years), as well as inclusion of both white and African American adults. We were also able to control for known influences of adipose tissue in our analyses such as age, race, smoking status and menopause (as appropriate). Although we were able to perform separate gender analyses, our sample was somewhat limited to perform separate race analyses. PCLS is a group of volunteers from Baton Rouge Louisiana and may not be generalizable to the overall population. Finally, we were not able to estimate ectopic liver and skeletal muscle fat, which were shown to differentiate MHO from OA. 11 Despite these limitations, we were able to use precise measures of adiposity from DXA and CT scans to assess differences in MHO and OA phenotypes separately in men and women.
In conclusion, we found that body composition did differ between MHO and OA phenotypes, in both men and women. Future research studies should confirm these results in different race/ethnicity and age groups. This information suggests that despite obesity, MHO adults store less overall adipose tissue and less centralized adipose tissue. These findings suggest that an OA individual may require more aggressive clinical treatment to address optimal health within the context of obesity, which targets not only the reduction in abnormal risk factors but also reductions in excess adipose tissue. 
